| Symbol | SXTP |
|---|---|
| Name | 60 DEGREES PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1025 CONNECTICUT AVENUE NW SUITE 1000, WASHINGTON, District of Columbia, 20036, United States |
| Telephone | +1 202 - 327-5422 |
| Fax | — |
| — | |
| Website | https://www.60degreespharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001946563 |
| Description | 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Companys pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue. Additional info from NASDAQ: |
New Form DEL AM - 60 DEGREES PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001213900-26-090587 <b>Size:</b> 6 KB
Read more60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Read more60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
Read moreNew Form 3 - 60 DEGREES PHARMACEUTICALS, INC. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001213900-26-082796 <b>Size:</b> 4 KB
Read moreNew Form SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001213900-26-082794 <b>Size:</b> 7 KB
Read more60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
Read moreNew Form DEF 14A - 60 DEGREES PHARMACEUTICALS, INC. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0001213900-26-074961 <b>Size:</b> 1 MB
Read more60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Read moreDirector DOW GEOFFREY S 🟢 acquired 7.3K shares of 60 DEGREES PHARMACEUTICALS, INC. (SXTP) at $1.38 Transaction Date: Jun 12, 2026 | Filing ID: 068853
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06478641 | Expanded Use in Persistent (B. Microti) Babesiosis | — | Persistent Babesiosis | Available | — | — | ClinicalTrials.gov |
| NCT06656351 | B-FREE Chronic Babesiosis Study | Phase2 | Chronic Babesiosis | Recruiting | 2025-11-18 | 2027-09-01 | ClinicalTrials.gov |
| NCT06207370 | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for… | Phase2 | Babesiosis | Recruiting | 2024-06-17 | 2027-07-01 | ClinicalTrials.gov |
| NCT04533347 | Tafenoquine in Patients With Mild to Moderate COVID-19 | Phase2 | COVID 19 Disease | Completed | 2021-02-19 | 2022-06-30 | ClinicalTrials.gov |
| NCT02569827 | Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated… | Phase1 | Dengue Fever | Withdrawn | 2018-12-01 | 2019-08-08 | ClinicalTrials.gov |
| NCT03320174 | Long-Term Safety Study of Tafenoquine | Phase2 | Healthy Volunteers | Completed | 2017-10-05 | 2021-07-13 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Modipafant 100mg | Other | Phase PHASE1 | Dengue Fever | WITHDRAWN | NCT02569827 |
| Placebo | Other | Phase PHASE1 | Dengue Fever | WITHDRAWN | NCT02569827 |
| Modipafant 50mg | Other | Phase PHASE1 | Dengue Fever | WITHDRAWN | NCT02569827 |
| Celgosivir | Other | Phase PHASE1 | Dengue Fever | WITHDRAWN | NCT02569827 |
| Placebo | Other | Phase PHASE2 | COVID 19 Disease | COMPLETED | NCT04533347 |
| Tafenoquine Oral Tablet | Other | Phase PHASE2 | COVID 19 Disease | COMPLETED | NCT04533347 |
| Tafenoquine 100mg | Other | Phase PHASE2 | Chronic Babesiosis | RECRUITING | NCT06656351 |
| Tafenoquine | Other | Preclinical | Persistent Babesiosis | AVAILABLE | NCT06478641 |
| Placebo | Other | Phase PHASE2 | Babesiosis | RECRUITING | NCT06207370 |
| Tafenoquine | Other | Phase PHASE2 | Babesiosis | RECRUITING | NCT06207370 |
| Placebo | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03320174 |
| Tafenoquine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03320174 |
| Placebo | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03320174 |
| Tafenoquine | Other | Phase PHASE2 | Healthy Volunteers | COMPLETED | NCT03320174 |